Literature DB >> 9593760

Functional overlap between murine Inpp5b and Ocrl1 may explain why deficiency of the murine ortholog for OCRL1 does not cause Lowe syndrome in mice.

P A Jänne1, S F Suchy, D Bernard, M MacDonald, J Crawley, A Grinberg, A Wynshaw-Boris, H Westphal, R L Nussbaum.   

Abstract

The oculocerebrorenal syndrome of Lowe (OCRL) is an X-linked human genetic disorder characterized by mental retardation, congenital cataracts, and renal tubular dysfunction. The Lowe syndrome gene, OCRL1, encodes a phosphatidylinositol 4,5-bisphosphate 5-phosphatase in the Golgi complex. The pathogenesis of Lowe syndrome due to deficiency of a phosphatidylinositol 4,5-bisphosphate 5-phosphatase in the Golgi complex is unknown. We have used targeted disruption in embryonic stem cells to make mice deficient in Ocrl1, the mouse homologue for OCRL1, as an animal model for the disease. Surprisingly, mice deficient in Ocrl1 do not develop the congenital cataracts, renal Fanconi syndrome, or neurological abnormalities seen in the human disorder. We hypothesized that Ocrl1 deficiency is complemented in mice by inositol polyphosphate 5-phosphatase (Inpp5b), an autosomal gene that encodes a phosphatidylinositol bisphosphate 5-phosphatase highly homologous to Ocrl1. We created mice deficient in Inpp5b; the mice were viable and fertile without phenotype except for testicular degeneration in males beginning after sexual maturation. We crossed mice deficient in Ocrl1 to mice deficient in Inpp5b. No liveborn mice or embryos lacking both enzymes were found, demonstrating that Ocrl1 and Inpp5b have overlapping functions in mice and suggesting that the lack of phenotype in Ocrl1-deficient mice may be due to compensating Inpp5b function.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9593760      PMCID: PMC508792          DOI: 10.1172/JCI2414

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  29 in total

1.  Tissue distribution and intracellular localisation of the 75-kDa inositol polyphosphate 5-phosphatase.

Authors:  C J Speed; M Matzaris; P I Bird; C A Mitchell
Journal:  Eur J Biochem       Date:  1995-11-15

2.  Cell lines from kidney proximal tubules of a patient with Lowe syndrome lack OCRL inositol polyphosphate 5-phosphatase and accumulate phosphatidylinositol 4,5-bisphosphate.

Authors:  X Zhang; P A Hartz; E Philip; L C Racusen; P W Majerus
Journal:  J Biol Chem       Date:  1998-01-16       Impact factor: 5.157

3.  Mouse models of Tay-Sachs and Sandhoff diseases differ in neurologic phenotype and ganglioside metabolism.

Authors:  K Sango; S Yamanaka; A Hoffmann; Y Okuda; A Grinberg; H Westphal; M P McDonald; J N Crawley; K Sandhoff; K Suzuki; R L Proia
Journal:  Nat Genet       Date:  1995-10       Impact factor: 38.330

4.  Targeted disruption of the Hexa gene results in mice with biochemical and pathologic features of Tay-Sachs disease.

Authors:  S Yamanaka; M D Johnson; A Grinberg; H Westphal; J N Crawley; M Taniike; K Suzuki; R L Proia
Journal:  Proc Natl Acad Sci U S A       Date:  1994-10-11       Impact factor: 11.205

5.  The oculocerebrorenal syndrome gene product is a 105-kD protein localized to the Golgi complex.

Authors:  I M Olivos-Glander; P A Jänne; R L Nussbaum
Journal:  Am J Hum Genet       Date:  1995-10       Impact factor: 11.025

6.  Evidence for a discrete behavioral phenotype in the oculocerebrorenal syndrome of Lowe.

Authors:  L Kenworthy; L Charnas
Journal:  Am J Med Genet       Date:  1995-11-20

7.  Mapping of the 75-kDa inositol polyphosphate-5-phosphatase (Inpp5b) to distal mouse chromosome 4 and its exclusion as a candidate gene for dysgenetic lens.

Authors:  P A Jänne; J M Rochelle; P A Martin-DeLeon; D Stambolian; M F Seldin; R L Nussbaum
Journal:  Genomics       Date:  1995-07-20       Impact factor: 5.736

8.  Tightly linked flanking markers for the Lowe oculocerebrorenal syndrome, with application to carrier assessment.

Authors:  D S Reilly; R A Lewis; D H Ledbetter; R L Nussbaum
Journal:  Am J Hum Genet       Date:  1988-05       Impact factor: 11.025

9.  Fibroblast growth factor receptor 3 is a negative regulator of bone growth.

Authors:  C Deng; A Wynshaw-Boris; F Zhou; A Kuo; P Leder
Journal:  Cell       Date:  1996-03-22       Impact factor: 41.582

10.  Lowe syndrome, a deficiency of phosphatidylinositol 4,5-bisphosphate 5-phosphatase in the Golgi apparatus.

Authors:  S F Suchy; I M Olivos-Glander; R L Nussabaum
Journal:  Hum Mol Genet       Date:  1995-12       Impact factor: 6.150

View more
  73 in total

Review 1.  Designing phenotyping studies for genetically engineered mice.

Authors:  C J Zeiss; J M Ward; H G Allore
Journal:  Vet Pathol       Date:  2011-09-19       Impact factor: 2.221

2.  The inositol Inpp5k 5-phosphatase affects osmoregulation through the vasopressin-aquaporin 2 pathway in the collecting system.

Authors:  Eileen Pernot; Sara Terryn; Siew Chiat Cheong; Nicolas Markadieu; Sylvie Janas; Marianne Blockmans; Monique Jacoby; Valérie Pouillon; Stéphanie Gayral; Bernard C Rossier; Renaud Beauwens; Christophe Erneux; Olivier Devuyst; Stéphane Schurmans
Journal:  Pflugers Arch       Date:  2011-09-22       Impact factor: 3.657

3.  Mouse model for Lowe syndrome/Dent Disease 2 renal tubulopathy.

Authors:  Susan P Bothwell; Emily Chan; Isa M Bernardini; Yien-Ming Kuo; William A Gahl; Robert L Nussbaum
Journal:  J Am Soc Nephrol       Date:  2010-12-23       Impact factor: 10.121

4.  OCRL1 mutations in patients with Dent disease phenotype in Japan.

Authors:  Takashi Sekine; Kandai Nozu; Rashmi Iyengar; Xue Jun Fu; Masafumi Matsuo; Ryojiro Tanaka; Kazumoto Iijima; Emiko Matsui; Yutaka Harita; Jun Inatomi; Takashi Igarashi
Journal:  Pediatr Nephrol       Date:  2007-03-24       Impact factor: 3.714

5.  Phosphoinositide phosphatases and disease.

Authors:  Philip W Majerus; John D York
Journal:  J Lipid Res       Date:  2008-11-11       Impact factor: 5.922

6.  A PH domain within OCRL bridges clathrin-mediated membrane trafficking to phosphoinositide metabolism.

Authors:  Yuxin Mao; Daniel M Balkin; Roberto Zoncu; Kai S Erdmann; Livia Tomasini; Fenghua Hu; Moonsoo M Jin; Michael E Hodsdon; Pietro De Camilli
Journal:  EMBO J       Date:  2009-06-18       Impact factor: 11.598

7.  A role of the Lowe syndrome protein OCRL in early steps of the endocytic pathway.

Authors:  Kai S Erdmann; Yuxin Mao; Heather J McCrea; Roberto Zoncu; Sangyoon Lee; Summer Paradise; Jan Modregger; Daniel Biemesderfer; Derek Toomre; Pietro De Camilli
Journal:  Dev Cell       Date:  2007-09       Impact factor: 12.270

8.  Abnormal bradykinin signalling in fibroblasts deficient in the PIP(2) 5-phosphatase, ocrl1.

Authors:  S F Suchy; J C Cronin; R L Nussbaum
Journal:  J Inherit Metab Dis       Date:  2009-01-28       Impact factor: 4.982

9.  The 5-phosphatase OCRL mediates retrograde transport of the mannose 6-phosphate receptor by regulating a Rac1-cofilin signalling module.

Authors:  Vanessa A van Rahden; Kristina Brand; Juliane Najm; Joerg Heeren; Suzanne R Pfeffer; Thomas Braulke; Kerstin Kutsche
Journal:  Hum Mol Genet       Date:  2012-08-19       Impact factor: 6.150

10.  X-inactivation analysis of embryonic lethality in Ocrl wt/-; Inpp5b-/- mice.

Authors:  David J Bernard; Robert L Nussbaum
Journal:  Mamm Genome       Date:  2010-02-27       Impact factor: 2.957

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.